KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Equity Average (2021 - 2025)

Historic Equity Average for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Q3 2025 value amounting to $983.0 million.

  • Recursion Pharmaceuticals' Equity Average rose 7728.4% to $983.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $983.0 million, marking a year-over-year increase of 7728.4%. This contributed to the annual value of $749.1 million for FY2024, which is 5783.31% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Equity Average stood at $983.0 million, which was up 7728.4% from $926.5 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Equity Average's 5-year high stood at $984.4 million during Q1 2025, with a 5-year trough of -$219.7 million in Q1 2021.
  • Over the past 5 years, Recursion Pharmaceuticals' median Equity Average value was $465.6 million (recorded in 2022), while the average stood at $525.0 million.
  • Over the last 5 years, Recursion Pharmaceuticals' Equity Average had its largest YoY gain of 33593.37% in 2022, and its largest YoY loss of 3351.19% in 2022.
  • Recursion Pharmaceuticals' Equity Average (Quarter) stood at $571.0 million in 2021, then fell by 23.48% to $436.9 million in 2022, then rose by 3.15% to $450.7 million in 2023, then skyrocketed by 72.99% to $779.7 million in 2024, then rose by 26.08% to $983.0 million in 2025.
  • Its last three reported values are $983.0 million in Q3 2025, $926.5 million for Q2 2025, and $984.4 million during Q1 2025.